A new advocacy group advocating policies favorable to the pharmaceutical industry last week immediately faced, and pushed back against, accusations that it is a front for the pharmaceutical lobby, and declined to disclose who gave it funding.
The small lobbying firm CGCN Group said on Friday that it created the new group, the Alliance to Protect Medical Innovation. Drug pricing reform activists and several reports questioned who was behind the group earlier in the week, after the alliance sprung into life the previous week with no mention of who is on the staff or who funds it.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.